Primary tumor resection for initially staged IV breast cancer An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival

Erol, TİMUÇİN; İmamoğlu, NE; Aydin, B; Taşkiran, ZİHNİ; Esendağli, GÜNEŞ; Kösemehmetoğlu, KEMAL; Baykal, A

doi:10.1097/md.0000000000016773

Primary tumor resection for initially staged IV breast cancer An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival

Atıf İçin Kopyala

Erol T., İmamoğlu N., Aydin B., Taşkiran Z. E., Esendağli G., Kösemehmetoğlu K., ...Daha Fazla

MEDICINE, cilt.98, sa.33, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 98 Sayı: 33
Basım Tarihi: 2019
Doi Numarası: 10.1097/md.0000000000016773
Dergi Adı: MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: breast, cancer, checkpoint blockade, immunotherapy, PD-L1, PD-L1 EXPRESSION, CLINICAL-SIGNIFICANCE, SURGICAL RESECTION, POOR-PROGNOSIS, CELLS, HETEROGENEITY, PREDICTS, THERAPY, PDL1
Hacettepe Üniversitesi Adresli: Evet

Özet

Conventional therapy modalities for advanced breast cancer are problematic, whereas checkpoint blockade immunotherapy has been considered as a promising approach. This study aims to determine programmed death-ligand 1 (PD-L1) expression and methylation status of PD-L1 promoter in primary tumor tissue and metastatic foci of patients with stage IV breast cancer.